αvβ6自身抗体或可用于预测溃疡性结肠炎
创作:aluba 审核:aluba 01月17日
  • 纳入82名UC患者与82名对照,收集确诊前10年、确诊前4年、确诊前2年及确诊时的血清样本;
  • 在确诊前10年,UC患者的αvβ6自身抗体水平即显著高于对照;
  • 从确诊前10年到确诊时,UC患者的αvβ6自身抗体血清阳性率从12.2%升至52.4%,对照平均为2.7%;
  • 在12名pre-UC患者(随后确诊UC)及49名对照组成的验证队列中,αvβ6自身抗体同样存在于pre-UC患者的血清样本中;
  • 较高的αvβ6自身抗体水平与较差的UC结局(住院、结肠切除术等)相关。
主编推荐语
aluba
Gastroenterology上发表的一项最新研究结果,发现在溃疡性结肠炎(UC)确诊前10年,血清中的抗整合素αvβ6自身抗体水平已显著高于对照,且较高的αvβ6自身抗体水平与较差的UC结局相关。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:33.883]

Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis

抗整合素αvβ6自身抗体可作为先于溃疡性结肠炎的新型生物标志物

10.1053/j.gastro.2022.12.042

01-09, Article

Abstract & Authors:展开

Abstract:收起
Background and Aims: Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. Anti-integrin αvβ6 autoantibodies (anti-αvβ6) have been described in UC patients. Here, we tested for the presence of anti-αvβ6 antibodies in the pre-clinical phase of UC and studied their association with disease-related outcomes after diagnosis.
Methods: Anti-αvβ6 were measured in 4 longitudinal serum samples collected from 82 subjects who later developed UC and 82 matched controls from a Department of Defense pre-clinical cohort (PREDICTS). In a distinct, external validation cohort (GEM), we tested 12 pre-UC subjects and 49 matched controls. Further, anti-αvβ6 were measured in 2 incident UC cohorts (COMPASS n=55 and OSCCAR n=104) and associations between anti-αvβ6 and UC-related outcomes were defined using Cox proportional-hazards model.
Results: Anti-αvβ6 were significantly higher among individuals who developed UC compared to controls up to 10 years before diagnosis in PREDICTS. The anti-αvβ6 seropositivity was 12.2% 10 years before diagnosis and increased to 52.4% at the time of diagnosis in subjects who developed UC compared with 2.7% in controls across the 4 timepoints. Anti-αvβ6 predicted UC development with an AUC of at least 0.8 up to 10 years before diagnosis. The presence of anti-αvβ6 in pre-clinical UC samples was validated in the GEM cohort. Finally, high anti-αvβ6 was associated with a composite of adverse UC-outcomes including hospitalization, disease extension, colectomy, systemic steroid use and/or escalation to biologic therapy in recently diagnosed UC.
Conclusion: Anti-integrin αvβ6 auto-antibodies precede the clinical diagnosis of UC by up to 10 years and are associated with adverse UC-related outcomes.

First Authors:
Alexandra E Livanos

Correspondence Authors:
Jean Frederic Colombel,Saurabh Mehandru

All Authors:
Alexandra E Livanos,Alexandra Dunn,Jeremy Fischer,Ryan C Ungaro,Williams Turpin,Sun-Ho Lee,Shumin Rui,Diane Marie Del Valle,Julia J Jougon,Gustavo Martinez-Delgado,Mark S Riddle,Joseph A Murray,Renee M Laird,Joana Torres,Manasi Agrawal,Jared S Magee,Thierry Dervieux,Sacha Gnjatic,Dean Sheppard,Bruce E Sands,Chad K Porter,Kenneth Croitoru,Francesca Petralia,CCC-GEM Project Research Consortium,OSCCAR Consortium,Jean Frederic Colombel,Saurabh Mehandru

评论